OncoSec Medical Inc. (NASDAQ:ONCS)‘s stock had its “buy” rating reissued by Maxim Group in a report issued on Wednesday.

The analysts wrote, “Analysts Offer Insights on Healthcare Companies: OncoSec Medical (NASDAQ: ONCS) and Heron Therapeutics (NASDAQ: HRTX) | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=d205c9f391&wpp_id=459509’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Offer Insights on Healthcare Companies: OncoSec Medical (NASDAQ: ONCS) and Heron Therapeutics (NASDAQ: HRTX)”

Separately, Rodman & Renshaw assumed coverage on shares of OncoSec Medical in a research report on Thursday, July 21st. They set a “buy” rating and a $6.00 price objective for the company.

Shares of OncoSec Medical (NASDAQ:ONCS) opened at 1.67 on Wednesday. The company’s market cap is $32.00 million. The stock has a 50 day moving average of $1.76 and a 200 day moving average of $1.74. OncoSec Medical has a 12-month low of $1.36 and a 12-month high of $3.49.

OncoSec Medical (NASDAQ:ONCS) last posted its quarterly earnings data on Thursday, October 13th. The company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by $0.07. Equities research analysts predict that OncoSec Medical will post ($1.33) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in OncoSec Medical stock. Vanguard Group Inc. raised its position in OncoSec Medical Inc. (NASDAQ:ONCS) by 3.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 430,031 shares of the company’s stock after buying an additional 13,025 shares during the period. Vanguard Group Inc. owned approximately 2.44% of OncoSec Medical worth $705,000 at the end of the most recent reporting period. Institutional investors own 7.24% of the company’s stock.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer. The Company’s portfolio includes biologic immunology therapeutic product candidates intended to treat a range of tumor types.

5 Day Chart for NASDAQ:ONCS

Receive News & Stock Ratings for OncoSec Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Inc. and related stocks with our FREE daily email newsletter.